Anticoagulants, antiplatelets, and thrombolytics for the treatment and/or prophylaxis of venous and arterial thrombosis.
Researchers sought to determine the accuracy of established tools in predicting the risk of cardiovascular events in patients with CML receiving TKIs.
In a study of men with prostate cancer, the presence of pre-existing cardiovascular diseases was associated with higher risk of death from taking certain medications.
Risk for coronary artery disease significantly decreased for survivors with diagnosis in 80s, 90s versus 70s.
Ninefold higher cancer occurrence seen both before and after peripartum cardiomyopathy diagnosis
Risk for subsequent cancer up with development of interim CV events, including heart failure, MI.
A new study aims to address the conundrum of coagulation risk in patients hospitalized for hematologic malignancies.
Incidence of composite cardiovascular events decreased across increasing total MET hours/week.